Loading clinical trials...
Loading clinical trials...
Dasatinib in Patients With Waldenström Macroglobulinemia (WM) Progressing on Ibrutinib
Conditions
Interventions
Dasatinib
Locations
1
United States
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Start Date
November 4, 2019
Primary Completion Date
December 31, 2021
Completion Date
December 31, 2021
Last Updated
March 21, 2024
NCT07387471
NCT06510491
NCT01804686
NCT02269592
NCT05602363
NCT07231952
Lead Sponsor
Jorge J. Castillo, MD
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions